Technosphere insulin: An inhaled mealtime insulin for the treatment of type 1 and type 2 diabetes mellitus

Formulary

Volumn 46, Issue 1, 2011, Pages 14-17

  Phung, Olivia J ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFREZZA; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; PLACEBO; RECOMBINANT HUMAN INSULIN; TECHNOSPHERE INSULIN; UNCLASSIFIED DRUG;

ARTICLE; BEDTIME DOSAGE; COUGHING; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LUNG FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; SIDE EFFECT; WEIGHT GAIN;

EID: 79952390914     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Standards of medical care in diabetes-2010. Diabetes Care. Jan 2010;33(suppl 1):S11-S61.
2. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care.2009;32:193-203.
3. Peyrot M, Rubin R R, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673-2679. (Pubitemid 43951158)
4. Davidson MB, Mehta AE, Siraj ES. Inhaled human insulin: an inspiration for patients with diabetes mellitus? Cleve Clin J Med. 2006;73:569-578. (Pubitemid 43880987)
5. de Galan BE, Simsek S, Tack CJ, Heine RJ. Efficacy and safety of inhaled insulin in the treatment of diabetes mellitus. Neth J Med. 2006;64:319-325. (Pubitemid 44614415)
6. Freemantle N, Blonde L, Duhot D, et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care. 2005;28:427-428. (Pubitemid 40170954)
7. Pfizer, Inc. Exubera (inhaled human insulin) package insert. New York, NY; 2006.
8. Richardson PC, Boss AH. Technosphere insulin technology. Diabetes Technol Ther. Jun 2007;9(suppl 1):S65-S72.
9. Rave K, Potocka E, Boss AH, Marino M, Costello D, Chen R. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab. 2009;11:715-720.
10. Rosenstock J, Bergenstal R, Defronzo RA, et al. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents. Diabetes Care. 2008;31:2177-2182.
11. Tack CJ, Christov V, de Galan BE, et al. Randomized forced titration to different doses of technosphere insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetes. J Diabetes Sci Technol. 2008;2:47-57.
12. Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet. 2010;375:2244-2253.